Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/352567
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study |
Autor: | Ocio, Enrique M. CSIC ORCID ; Montes, Carmen; Bustamante, Gabriela; Garzón, Sebastián; González, Esther; Pérez-Persona, Ernesto; González-Calle, Verónica; Sirvent, Maialen; Arguiñano, José M.; González, Yolanda; Ríos, Rafael; Miguel Llorente, Dunia de; Grande, Marta; Fernández-Nistal, Alonso; Naves, Andrea; Rosiñol, Laura | Palabras clave: | Burden Cost of illness Multiple myeloma Therapy Monoclonal gammopathy |
Fecha de publicación: | oct-2023 | Editor: | Elsevier | Citación: | Clinical Lymphoma, Myeloma and Leukemia 23(10): e341-e347 (2023) | Resumen: | [Background]: Most patients with multiple myeloma (MM) relapse or become refractory, resulting in high health care costs. However, real-world data regarding the utilization of health care services among the relapsed/refractory MM (RRMM) population are scarce. [Methods]: Observational, cross-sectional, multicenter study of the utilization of health care services by RRMM patients who had relapsed within the previous 6 months in Spain in a real-world setting. Data were collected from the clinical records and during a single structured interview and included sociodemographic and clinical characteristics at last relapse, the treatment and health care services nature, and were presented using descriptive statistics. [Results]: The 276 patients enrolled (53.3% males), with a mean [SD] age of 67.4 [10.5] years, had experienced their most recent relapse a median (IQR) of 1.61 (0.74, 3.14) months before entering the study. Patients lived a median (IQR) of 9.0 (3.0, 30.0) km away from the hospital and visited the hospital a median (IQR) of 3.0 (2.0, 5.0) times/month to receive treatment for their most recent relapse. They spent a median (IQR) of 15.84 (5.0, 42.0) euros/month on transportation. Since their most recent relapse, most patients had been admitted to a hospital unit (n = 155, 56.2%), had required ≥1 diagnostic tests (n = 227, 82.2%), and had consulted the hematologist (n = 270, 97.8%) a mean (SD) of 5.5 (5.4) times. In half of the visits, patients were accompanied by an actively working caregiver (n = 112, 54.4%). [Conclusions]: RRMM treatments are associated with a high utilization of health care services and pose a significant burden for patients and caregivers. |
Versión del editor: | https://doi.org/10.1016/j.clml.2023.07.006 | URI: | http://hdl.handle.net/10261/352567 | DOI: | 10.1016/j.clml.2023.07.006 | ISSN: | 2152-2650 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Real-World Health Care_Ocio_Art_2023.pdf | 340,61 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
1
checked on 20-abr-2024
Page view(s)
20
checked on 29-abr-2024
Download(s)
3
checked on 29-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons